Literature DB >> 22169130

Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension.

Stevo Julius1, Paolo Palatini, Sverre E Kjeldsen, Alberto Zanchetti, Michael A Weber, Gordon T McInnes, Hans R Brunner, Giuseppe Mancia, M Anthony Schork, Tsushung A Hua, Bjoern Holzhauer, Dion Zappe, Silja Majahalme, Kenneth Jamerson, Nevres Koylan.   

Abstract

A high heart rate (HR) predicts future cardiovascular events. We explored the predictive value of HR in patients with high-risk hypertension and examined whether blood pressure reduction modifies this association. The participants were 15,193 patients with hypertension enrolled in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial and followed up for 5 years. The HR was assessed from electrocardiographic recordings obtained annually throughout the study period. The primary end point was the interval to cardiac events. After adjustment for confounders, the hazard ratio of the composite cardiac primary end point for a 10-beats/min of the baseline HR increment was 1.16 (95% confidence interval 1.12 to 1.20). Compared to the lowest HR quintile, the adjusted hazard ratio in the highest quintile was 1.73 (95% confidence interval 1.46 to 2.04). Compared to the pooled lower quintiles of baseline HR, the annual incidence of primary end point in the top baseline quintile was greater in each of the 5 study years (all p <0.05). The adjusted hazard ratio for the primary end point in the highest in-trial HR heart rate quintile versus the lowest quintile was 1.53 (95% confidence interval 1.26 to 1.85). The incidence of primary end points in the highest in-trial HR group compared to the pooled 4 lower quintiles was 53% greater in patients with well-controlled blood pressure (p <0.001) and 34% greater in those with uncontrolled blood pressure (p = 0.002). In conclusion, an increased HR is a long-term predictor of cardiovascular events in patients with high-risk hypertension. This effect was not modified by good blood pressure control. It is not yet known whether a therapeutic reduction of HR would improve cardiovascular prognosis. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169130     DOI: 10.1016/j.amjcard.2011.10.025

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

1.  Associations between age, cohort, and urbanization with SBP and DBP in China: a population-based study across 18 years.

Authors:  Samantha M Attard; Amy H Herring; Bing Zhang; Shufa Du; Barry M Popkin; Penny Gordon-Larsen
Journal:  J Hypertens       Date:  2015-05       Impact factor: 4.844

Review 2.  Heart rate and the cardiometabolic risk.

Authors:  Paolo Palatini
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

Review 3.  Heart rate and blood pressure: any possible implications for management of hypertension?

Authors:  Scott Reule; Paul E Drawz
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

4.  Association Between Heart Rate and Subclinical Cerebrovascular Disease in the Elderly.

Authors:  Koki Nakanishi; Zhezhen Jin; Shunichi Homma; Mitchell S V Elkind; Tatjana Rundek; Seitetz C Lee; Aylin Tugcu; Mitsuhiro Yoshita; Charles DeCarli; Clinton B Wright; Ralph L Sacco; Marco R Di Tullio
Journal:  Stroke       Date:  2017-12-28       Impact factor: 7.914

5.  Association between resting heart rate and coronary artery disease, stroke, sudden death and noncardiovascular diseases: a meta-analysis.

Authors:  Dongfeng Zhang; Weijing Wang; Fang Li
Journal:  CMAJ       Date:  2016-08-22       Impact factor: 8.262

6.  Tachycardia: The hidden cardiovascular risk factor in uncomplicated arterial hypertension.

Authors:  Katarzyna Cierpka-Kmieć; Dagmara Hering
Journal:  Cardiol J       Date:  2019-02-25       Impact factor: 2.737

7.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 8.  Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies.

Authors:  Kamila Lachowska; Marcin Gruchała; Krzysztof Narkiewicz; Dagmara Hering
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

9.  Heart rate and ischemic stroke: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.

Authors:  Wesley T O'Neal; Waqas T Qureshi; Suzanne E Judd; James F Meschia; Virginia J Howard; George Howard; Elsayed Z Soliman
Journal:  Int J Stroke       Date:  2015-08-26       Impact factor: 5.266

10.  Drug-resistant hypertensive patients responding to multielectrode renal denervation exhibit improved heart rate dynamics and reduced arrhythmia burden.

Authors:  C Tsioufis; V Papademetriou; D Tsiachris; K Dimitriadis; A Kasiakogias; A Kordalis; V Antonakis; A Kefala; C Thomopoulos; I Kallikazaros; E O-Y Lau; C Stefanadis
Journal:  J Hum Hypertens       Date:  2014-03-13       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.